Table 3.
Multivariate analysis with covariates adjustment of 120 patients with ovarian cancer
| Prognostic variables | OSa | PFSb | ||||
|---|---|---|---|---|---|---|
| HR | 95 % CI | P value | HR | 95 % CI | P value | |
| JARID1B expression | ||||||
| Low | ||||||
| High | 21.8 | 5.92,71.81 | <.001 | 17.85 | 6.31,50.51 | <.001 |
| Lymph node metastasis | ||||||
| Absent | ||||||
| Present | 0.772 | 0.44,1.35 | 0.36 | 0.93 | 0.55,1.59 | 0.81 |
| Histopathological differentiationc | ||||||
| G3 | ||||||
| G2 | 0.94 | 0.51,1.7 | 0.84 | 0.80 | 0.45,1.41 | 0.43 |
| G1 | 1.55 | 0.69,3.46 | 0.28 | 2.27 | 1.06,4.88 | 0.04 |
| Chemotherapy regimen | ||||||
| TP | ||||||
| PAC | 5.14 | 2.77,9.5 | <.001 | 4.53 | 2.58,7.96 | <.001 |
| Age (years) | ||||||
| <50 | ||||||
| ≥50 | 1.27 | 0.72,2.2 | 0.41 | 1.16 | 0.70,1.93 | 0.56 |
| FIGO stage | ||||||
| I and II | ||||||
| III and IV | 2.26 | 0.74,6.90 | 0.15 | 5.30 | 1.71,16.41 | 0.0038 |
| Residual tumor size | ||||||
| <1 cm | ||||||
| 1–2 cm | 0.79 | 0.42,1.51 | 0.48 | 0.92 | 0.50,1.71 | 0.80 |
| ≥2 cm | 4.078 | 1.7,9.80 | <.001 | 3.31 | 1.41,7.74 | <.001 |
OS overall survival time, PFS progression-free survival time, TP cisplatin and paclitaxel, PAC cisplatin, epirubicin, and cyclophosphamide
aLikelihood ratio test, P < .001
bLikelihood ratio test, P < .001
cG1 is well differentiated, G2 moderately differentiated, and G3 poorly differentiated